natural glp-1 alternatives Boost: Foods & Diet for Weight Loss Looking for a natural alternative

and Canada

In people with obesity and established cardiovascular disease but without diabetes, semaglutide 2.4 mg resulted in 20% reduction in major adverse cardiovascular events [(MACE), death from cardiovascular causes, nonfatal myocardial infarction or nonfatal stroke] compared to placebo (SELECT trial) after a mean follow-up of 39.8 months this is the first trial demonstrating cardiovascular benefit for an obesity pharmacotherapy [110]

Accessibility and cost remain a major challenge, restricting the availability of these potentially transformative drugs to many individuals who may benefit from them

Although some studies have raised concerns about pancreatitis and thyroid-related risks, the current evidence does not conclusively establish causality

Some of that data is coming soon, says Dr

95% CI 1.70 to 8.45)